Click in for more news from The Hill{beacon} Health Care Health Care   The Big Story Pharma industry loses on Medicare price ...

Federal judges in Texas and Connecticut on Thursday ruled against arguments challenging the constitutionality of the Medicare ...

Boehringer Ingelheim Pharmaceuticals Inc. failed to prove to an appeals court that a Biden-era drug pricing program aimed at ...

An appeals panel found that a pharmaceutical company's participation in Medicare's drug price negotiation program is ...

Our Drug Pricing and Market Access team tracks recent developments in healthcare reform, the Medicaid Drug Rebate Program, the 340B Program, ...

Boehringer Ingelheim Pharmaceuticals Inc. failed to prove to an appeals court that a Biden-era drug pricing program aimed at ...

The Trump administration has been talking to drugmakers about ways to raise prices of medicines in Europe and elsewhere to ...

Meridian Funds, managed by ArrowMark Partners, released its “Meridian Growth Fund” second-quarter 2025 investor letter. A ...

In the letters, Trump gave the pharmaceutical firms until Sept. 29 to make a series of commitments that aim to provide “immediate relief from the vastly inflated drug prices and put an end to the free ...

Learn about the benefits that become permanent features of Medicare in 2026 and how they have been changed or updated since ...

A normally hard-headed bench just endorsed President Biden’s scheme to dictate how much drugmakers can charge under Medicare.

On August 1, 2025, the Health Resources and Services Administration (“HRSA”) issued a Notice announcing the launch of the 340B Rebate Model ...